与流行和发病脆弱相关的晚期血蛋白:蛋白质组分析
Fangyu Liu1, Thomas R Austin2, Jennifer A Schrack1,3
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Aging cell
|September 12, 2023
概括
这项研究确定了与老年人身体虚弱和虚弱前期相关的关键血蛋白. 这些蛋白质为这种老年综合征提供了潜在的生物标志物和治疗点.
科学领域:
- 老年学是一门学科.
- 蛋白质组学是指蛋白质组学.
- 生物化学 生物化学
背景情况:
- 身体虚弱是一种老年综合征,预示着老年人的不良结果.
- 关于脆弱性的蛋白质学研究是有限的,特别是关于脆弱性前和意外脆弱性的研究.
- 了解脆弱的生物学基础对于开发干预措施至关重要.
研究的目的:
- 为了识别与脆弱性和脆弱性相关的血蛋白.
- 为了研究预测事件脆弱性发展的蛋白质.
- 探索与脆弱有关的生物途径和机制.
主要方法:
- 利用了来自4955个SOMAmers的蛋白质组数据在社区研究中的动脉样硬化风险 (N=3838,年龄≥65).
- 进行了预脆弱性和脆弱性的横截面分析,对共变量进行了调整.
- 验证了心血管健康研究中的发现,并进行了针对事件脆弱性的纵向分析.
主要成果:
- 分别确定了134个和179个与脆弱性和脆弱性相关的截面蛋白质.
- 在验证队列中复制了一组蛋白质子集;GDF15,TAGLN,IGFBP2和GHR显示出强烈的关联.
- 发现了包括TREM1和TAGLN在内的4种蛋白质,预测事件脆弱性,丰富脂质代谢,血管生成,炎症和衰老途径.
结论:
- 这项研究提供了脆弱性的综合蛋白质组概况,包括前期和临床阶段.
- 确定了特定的血蛋白 (例如,GDF15,TAGLN,IGFBP2,GHR) 作为脆弱性的潜在生物标志物.
- 揭示了失调的生物通路,为脆弱病因和潜在的干预目标提供了新的见解.
更多相关视频
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
16.6K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
Proteomics
7.4K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
7.4K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
82
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
82
